Description and validation of a Markov model of survival for individuals free of cardiovascular disease that uses Framingham risk factors

BMC Medical Informatics and Decision Making

Volumn 4, Issue , 2004, Pages

  Martin, Chris ^a   Vanderpump, Mark ^b   French, Joyce ^c  

^a Laindon Hlth Ctr Prim Care R T   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL;

ACCURACY; AGE DISTRIBUTION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; COMPARATIVE STUDY; CORRELATION ANALYSIS; DEATH; FOLLOW UP; HEALTH SURVEY; HUMAN; LIFE EXPECTANCY; MORTALITY; RISK FACTOR; SMOKING; SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM; VALIDATION PROCESS; ADULT; AGED; CARDIOVASCULAR DISEASES; COMPUTER SIMULATION; DECISION SUPPORT SYSTEM; FEMALE; MALE; MIDDLE AGED; PREDICTIVE VALUE; PROBABILITY; VALIDATION STUDY;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; COMPUTER SIMULATION; DECISION MAKING, COMPUTER-ASSISTED; FEMALE; GREAT BRITAIN; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SURVIVAL;

EID: 13444267631     PISSN: 14726947     EISSN: 14726947     Source Type: Journal    
DOI: 10.1186/1472-6947-4-6     Document Type: Article

References (25)

1. Anderson KM, Wilson PW, Odell PM, Kannel WB: An updated coronary risk profile. A statement for health professionals. Circulation 1991, 83:356-362.
2. Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R: Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 1998, 80 (Suppl 2):S1-29.
3. Department of Health: National Service Framework for Coronary Heart Disease: Main document. Department of Health 2000.
4. Baker S, Priest P, Jackson R: Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ 2000, 320:680-685.
5. Montgomery AA, Fahey T, Ben Shlomo Y, Harding J: The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis. J Hypertens 2003, 21:1753-1759.
6. Tsevat J, Weinstein MC, Williams LW, Tosteson AN, Goldman L: Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991, 83:1194-1201.
7. Lai D, Hardy RJ: Potential gains in life expectancy or years of potential life lost: impact of competing risks of death. Int J Epidemiol 1999, 28:894-898.
8. Lloyd-Jones DM, Larson MG, Beiser A, Levy D: Lifetime risk of developing coronary heart disease. Lancet 1999, 353:89-92.
9. Magni P, Quaglini S, Marchetti M, Barosi G: Deciding when to intervene: a Markov decision process approach. Int J Med Inf 2000, 60:237-253.
10. Pharoah PD, Hollingworth W: Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996, 312:1443-1448.
11. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L: Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987, 77:1417-1426.
12. Grover SA, Paquet S, Levinton C, Coupal L, Zowall H: Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. Arch Intern Med 1998, 158:655-662.
13. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decis Making 1993, 13:322-338.
14. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley EJ, Rodgers H, Tunbridge F, Young ET: The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid 1996, 6:155-160.
15. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA: Lipid profiles and cardiovascular disease in the Whickham area with particular reference to thyroid failure. Clin Endocrinol (Oxf) 1977, 7:495-508.
16. Office for National Statistics: Mortality Statistics: General: Series DH1 no. 31. The Stationery Office 1998.
17. Surgeon General: 1989 Surgeon General Report: Reducing the Health Consequences of Smoking. US Dept Health and Human Services 1989.
18. Erens B, Primatesta P: Health Survey for England: Cardiovascular Disease. National Statistical Office 1999.
19. Moore CR, Krakoff LR, Phillips RA: Confirmation or exclusion of stage I hypertension by ambulatory blood pressure monitoring. Hypertension 1997, 29:1109-1113.
20. Wollin SD, Jones PJ: Alcohol, red wine and cardiovascular disease. J Nutr 2001, 131:140 1-1404.
21. Manson JE, Greenland P, LaCroix AZ, Stefanick ML, Mouton CP, Oberman A, Perri MG, Sheps DS, Pettinger MB, Siscovick DS: Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002, 347:716-725.
22. Taylor DH Jr, Hasselblad V, Henley SJ, Thun MJ, Sloan FA: Benefits of smoking cessation for longevity. Am J Public Health 2002, 92:990-996.
23. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419.
24. Mackenbach JP, Kunst AE, Lautenbach H, Oei YB, Bijlsma F: Gains in life expectancy after elimination of major causes of death: revised estimates taking into account the effect of competing causes. J Epidemiol Community Health 1999, 53:32-37.
25. Hannerz H, Nielsen ML: Life expectancies among survivors of acute cerebrovascular disease. Stroke 2001, 32:1739-1744.